This article is more than 5 years old. Information may no longer be current.

Arthrosurface receives FDA 510(k) clearance for stemless total shoulder system

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Arthrosurface announced that it received FDA 510(k) clearance for the OVOMotion Shoulder Arthroplasty System, a stemless total shoulder system designed for patients with painful or severely disabled shoulder joints resulting from arthritis, traumatic events or avascular necrosis.

Providing increased exposure to the glenoid and minimizing bone removal, the OVOMotion Shoulder Arthroplasty System was cleared for use in conjunction with Arthrosurface’s Inlay Glenoid System, according to a company press release.

“The OVOMotion Shoulder Arthroplasty System is intended to be the first of a three-element modular stemless system that will ultimately allow surgeons to intraoperatively choose between stemless, traditional and reverse options,” Steve Ek, CEO of Arthrosurface, said in the release.

Reference:

www.arthrosurface.com/product-clinical/fda-clearance-ovomotion/